Bidding up shares of a company that sells genetically engineered mosquitoes seems painfully silly in hindsight. Intrexon’s (XON) net losses more than tripled. The company lost $0.55 per share. The difference between non-GAAP and GAAP EBITDA is massive. Why? Excluding stock compensation explains the wide GAAP to non-GAAP numbers. Despite the headline loss which drove shares lower by over six percent, Fibrocell’s FCX-013 is progressing. The company expects to submit an IND for FCX-013 next year (2017). ZIOPHARM is on target for launching three clinical programs this year. IT has three ongoing ones. They include:controlled IL-12 gene therapy in breadth in brain cancersNK cells against AMLnon-bio CAR T-cell therapies targeting CD-19 for leukemia and lymphomasviral CAR T-cell therapy for myeloid malignancies XOM still has a long way to go in recovering from the short attack (April 22). Keep XOM on your watch list. More biotech ideas?Why Acadia Pharmaceutical is on Fire, and Why It Won’t Last MannKind: SUNEdison 2.0 Valeant Contagion Spreads to Endo’s Stock Relypsa Looks Fine, Depending on the Timeframe Watch Kerx After the Dip